8-K: J&J Q3 Sales Up, Raises Outlook; Orthopaedics Spin-Off Planned

Johnson & Johnson reported strong third-quarter 2025 results, raising its full-year sales outlook, and announced its intent to separate its Orthopaedics business, DePuy Synthes.

Summary

• Reported sales for Q3 2025 increased by 6.8% to $24.0 billion, with operational growth of 5.4% and adjusted operational growth of 4.4%.
• Diluted earnings per share (EPS) for Q3 2025 were $2.12, a 91.0% increase, while adjusted EPS rose 15.7% to $2.80.
• Net earnings for Q3 2025 were $5.152 billion, up 91.2%, with adjusted net earnings at $6.801 billion, up 15.7%.
• The company raised its full-year 2025 estimated reported sales guidance to a midpoint of $93.7 billion (5.7% growth) from $93.4 billion (5.4% growth).
• Full-year adjusted EPS guidance was reaffirmed at a midpoint of $10.85 (8.7% growth), absorbing higher tax costs.
• Johnson & Johnson announced its intent to separate its Orthopaedics business, DePuy Synthes, to enhance strategic focus and accelerate portfolio shift towards higher-growth, higher-margin markets.
• Namal Nawana has been appointed Worldwide President of DePuy Synthes, effective immediately, to lead the business through the separation process and beyond.
• The Orthopaedics business generated approximately $9.2 billion in sales for fiscal year 2024.
• Significant innovation includes approvals for INLEXZO (bladder cancer) and TREMFYA (ulcerative colitis, pediatric plaque psoriasis, psoriatic arthritis), submission of icotrokinra (plaque psoriasis), and landmark data for RYBREVANT plus LAZCLUZE (NSCLC) and Impella Heart Pump (DanGer Shock trial).

Sentiment

Score: 8

Explanation: The filing presents strong Q3 financial results, including significant sales and EPS growth, and a raised full-year sales outlook. The strategic decision to separate the Orthopaedics business is framed as a value-enhancing move to focus on higher-growth, higher-margin areas, which is generally viewed positively by investors. The appointment of an experienced leader for the new entity further supports a positive outlook.

Positives

• Strong Q3 2025 reported sales growth of 6.8% to $24.0 billion.
• Significant increase in Q3 2025 reported EPS by 91.0% to $2.12 and adjusted EPS by 15.7% to $2.80.
• Raised full-year 2025 estimated reported sales guidance to a midpoint of $93.7 billion, reflecting a 5.7% growth.
• Innovative Medicine segment operational sales grew 5.3%, driven by key oncology and immunology products like DARZALEX, CARVYKTI, ERLEADA, RYBREVANT/LAZCLUZE, TREMFYA, and SPRAVATO.
• MedTech segment operational sales grew 5.6%, fueled by electrophysiology products, Abiomed, Shockwave, wound closure, and Surgical Vision.
• Strategic intent to separate the Orthopaedics business is expected to increase Johnson & Johnson's top-line growth and operating margins by focusing on higher-growth areas.
• The standalone DePuy Synthes is projected to be the largest, most comprehensive orthopaedics-focused company with leading market share.
• Multiple significant regulatory approvals and positive data releases for key pipeline assets, including INLEXZO, TREMFYA, RYBREVANT plus LAZCLUZE, and Impella Heart Pump.
• Reaffirmed full-year adjusted EPS guidance of $10.85 at the midpoint, despite absorbing higher tax costs.

Negatives

• Free Cash Flow (YTD estimated) decreased slightly to ~$14.2 billion in Q3 2025 from $14.471 billion in Q3 2024.
• Innovative Medicine growth was partially offset by an approximate (1,070) basis points impact from STELARA and IMBRUVICA.
• Research and development expense decreased by 25.8% in Q3 2025 to $3.672 billion compared to Q3 2024.
• Provision for taxes on income increased by 263.5% in Q3 2025 to $2.341 billion, resulting in a higher effective tax rate of 31.2% compared to 19.3% in Q3 2024.
• Restructuring expenses increased in Q3 2025, with $40 million for Orthopaedics and $128 million for Surgery.

Risks

• Economic factors, such as interest rate and currency exchange rate fluctuations or changes to applicable laws and regulations.
• Competition, including technological advances, new products, and patents attained by competitors.
• Challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals.
• Uncertainty of commercial success for new and existing products.
• Challenges to patents and the impact of patent expirations.
• The ability to successfully execute strategic plans, including restructuring plans.
• The impact of business combinations and divestitures.
• Manufacturing difficulties or delays, internally or within the supply chain.
• Product efficacy or safety concerns resulting in product recalls or regulatory action.
• Significant adverse litigation or government action, including related to product liability claims.
• Changes to applicable laws and regulations, including tax laws and global health care reforms.
• Trends toward health care cost containment.
• Changes in behavior and spending patterns of purchasers of health care products and services.
• Financial instability of international economies and legal systems and sovereign risk.
• Increased scrutiny of the health care industry by government agencies.
• The company's ability to satisfy the necessary conditions to consummate the separation of the Orthopaedics business on a timely basis or at all.
• The structure of the separation transaction and the successful separation of the Orthopaedics business and realization of anticipated benefits from the separation.

Future Outlook

Johnson & Johnson raised its full-year 2025 estimated reported sales guidance to a midpoint of $93.7 billion, representing 5.7% growth, and reaffirmed its full-year adjusted EPS guidance at a midpoint of $10.85, absorbing higher tax costs. The planned separation of the Orthopaedics business is expected to increase Johnson & Johnson's top-line growth and operating margins by allowing a sharpened focus on higher-growth areas.

Management Comments

• "Johnson & Johnson delivered another strong performance in the third quarter fueled by the depth and strength of our portfolio and significant progress across our pipeline."
• "With a sharpened focus on the six priority areas of Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision, Johnson & Johnson is in a new era of accelerated growth and innovation, with pioneering treatments that will continue to transform lives."
• "The planned separation reflects our long-standing commitment to portfolio optimization and value creation. We are confident that our Orthopaedics business will be better positioned to improve top-line growth and operating margins as a standalone business."
• "This move would further enhance the market-leading position for DePuy Synthes and strengthen our overall MedTech business with a focus on Cardiovascular, Surgery and Vision."
• "Namal brings extensive experience leading global public companies and a demonstrated track record of success in growing medical devices businesses. We are pleased to have an executive of Namals caliber step into this role and are confident he is the ideal leader to guide the new DePuy Synthes into the future."
• "I am honored to take on this role to lead the new DePuy Synthes, a global market leader with a deep heritage of innovation and a strong commercial platform that is well positioned to succeed as a standalone company. I look forward to working together with the broader team to meet our mission and keep people around the globe moving."

Industry Context

The announcement reflects a broader industry trend among diversified healthcare conglomerates to streamline operations and focus on core, high-growth segments. By separating its Orthopaedics business, Johnson & Johnson aims to unlock value by allowing both entities to pursue distinct strategic priorities and capital allocation strategies. This move aligns with other major pharmaceutical and medical device companies that have spun off less synergistic or slower-growth divisions to enhance agility and investor focus on specific market opportunities. The focus on Innovative Medicine and higher-growth MedTech areas like Cardiovascular, Surgery, and Vision positions Johnson & Johnson to compete more effectively in rapidly evolving therapeutic and technological landscapes.

Comparison to Industry Standards

• DePuy Synthes, upon separation, is expected to be the largest, most comprehensive orthopaedics-focused company in the world, with leading market share positions across major categories, indicating a strong competitive standing within the orthopaedics sector.
• The strategic move to focus on high-growth, high-margin markets within Innovative Medicine (Oncology, Immunology, Neuroscience, Cardiovascular) and MedTech (Cardiovascular, Surgery, Vision) aligns with strategies seen in other leading global healthcare companies like Pfizer (which spun off its Upjohn generics business) or GSK (which spun off its consumer healthcare business, Haleon), aiming to enhance growth profiles and operating margins.

Management Changes

Legal Proceedings

• Pre-tax adjustments for litigation related items were $15 million in Q3 2025, significantly lower than $2,388 million in Q3 2024.
• The forward-looking statements section mentions "significant adverse litigation or government action, including related to product liability claims" as a potential risk.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value through portfolio optimization, enhanced focus on high-growth areas, and improved operating margins for Johnson & Johnson. The Orthopaedics business, as DePuy Synthes, is also expected to improve top-line growth and operating margins as a standalone entity.
• Employees: The separation process will involve changes for employees within the Orthopaedics business, with consultations with works councils and other employee representative bodies as required. Namal Nawana's appointment aims to ensure long-term success for the DePuy Synthes team.
• Customers: Both Johnson & Johnson and the future DePuy Synthes aim to continue serving customers and advancing patient care with pioneering treatments and comprehensive orthopaedics solutions.
• Creditors: DePuy Synthes is expected to have an investment-grade profile and strong balance sheet, indicating continued financial stability. Johnson & Johnson remains committed to maintaining a strong balance sheet.

Next Steps

• Johnson & Johnson will continue to operate its Orthopaedics business in alignment with its current strategy, including continued investments in growth, margin improvement, and innovation, as the separation proceeds.
• The company intends to explore multiple paths to effect the planned separation of the Orthopaedics business.
• The target completion for the Orthopaedics separation is within 18 to 24 months, subject to conditions including consultations with works councils, Board of Directors approval, and regulatory approvals.
• Johnson & Johnson will host a conference call with investors to discuss Q3 results and the proposed separation on October 14, 2025, at 8:30 a.m., Eastern Time.

Key Dates

Recommendation

The filing demonstrates robust financial performance in Q3 2025, with strong sales and EPS growth, coupled with a raised full-year sales outlook. The strategic decision to spin off the Orthopaedics business is a significant positive, as it allows Johnson & Johnson to sharpen its focus on higher-growth, higher-margin Innovative Medicine and MedTech segments, which is expected to enhance overall growth and profitability. The new DePuy Synthes is also positioned for success as a market leader in orthopaedics. This strategic clarity, combined with strong operational execution and a healthy pipeline of innovations, makes Johnson & Johnson an attractive investment.

Keywords

Johnson & Johnson, JNJ, Q3 2025 Earnings, SEC Filing, Orthopaedics Separation, DePuy Synthes, Innovative Medicine, MedTech, Pharmaceuticals, Medical Devices, Biotechnology, Healthcare, Financial Results, Sales Outlook, EPS, DARZALEX, CARVYKTI, TREMFYA, RYBREVANT, LAZCLUZE, INLEXZO, SPRAVATO, Abiomed, Shockwave, Corporate Restructuring, Spin-off